Consolidated Statements of Operations (USD $) In Thousands, except Per Share data, unless otherwise specified	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Net Revenues	$ 30,082	$ 20,371
Operating Expenses
Cost of sales (excluding depreciation and amortization)	9,974	9,167
Research and development	1,712	1,158
Selling, general and administrative	16,388	9,521
Depreciation and amortization	1,110	567
Total Operating Expenses	29,184	20,413
Operating Income/(Loss) from Continuing Operations	898	(42)
Other Expense
Interest expense	(467)	(1,327)
Other expense	(305)	(241)
Net Income/(Loss) from Continuing Operations Before Benefit for Income Taxes	126	(1,610)
(Provision)/Benefit for income taxes	(20)	36
Net Income/(Loss) from Continuing Operations	106	(1,574)
Discontinued Operation
Gain on discontinued operation, net of provision (benefit) for income taxes	195	68
Net Income/(Loss)	301	(1,506)
Computation of Income/(Loss) from Continuing Operations Attributable to Common Stockholders:
Net Income/(Loss) from Continuing Operations	106	(1,574)
Preferred stock dividends	(4,975)	(6,922)
(Loss) from Continuing Operations Attributable to Common Stockholders	$ (4,869)	$ (8,496)
Basic and Diluted Income/(Loss) Per Share:
Continuing operations (in dollars per share)	$ (0.96)	$ 0	[1]
Discontinued operation (in dollars per share)	$ 0.04	$ 0	[1]
Basic and Diluted Income/(Loss) Per Share (in dollars per share)	$ (0.92)	$ 0	[1]
Basic and Diluted Weighted-Average Shares Outstanding (in shares)	5,071	0	[1]

[1] Earnings per common share is not calculable because common shareholders from ANIP Acquisition Company did not receive consideration from the June 19, 2013 Merger with BioSante. See Note 1 for further details.